PIC® Camborough® Maternal By-Product Barrows Perform Better than Industry Competitor in Wean-to-Finish Growth Performance  

Half of a terminal pig’s genetics are inherited from the maternal line, making the sow’s contribution to key performance traits essential. PIC focuses not only on the robustness and reproductive success of the PIC® Camborough® but also on her influence on progeny performance.  

In a recent trial, Camborough maternal barrows showcased a significant economic advantage, driven by higher growth rates and superior feed conversion compared to maternal barrows from a competitor line. 

Camborough Barrows Deliver Economic and Performance Advantage 

Camborough maternal barrows are more economically competitive than their competitor counterparts. These barrows deliver exceptional growth and enhanced feed efficiency, resulting in an economic benefit of $3.14 per pig placed1

This graph shows that Camborough maternal barrows demonstrate aan economic benefit of $3.14 per pig placed.

Growth rate and feed efficiency are critical drivers of profitability. Camborough maternal barrows excel in both areas, achieving a significant advantage in feed efficiency without compromising growth rate. 

Performance Metrics:  

Wean-to-Finish Average Daily Gain (ADG): Camborough barrows outperformed competitor barrows with a wean-to-finish ADG of 1.93 compared to 1.911, a statistically significant difference (P ≤ 0.05). 

Feed Efficiency: Camborough barrows demonstrated a 0.081 improvement in adjusted feed efficiency over competitor female progeny, a difference that was also statistically significant. 

Camborough barrows demonstrated a 0.08 improvement in feed efficiency over competitor female progeny, a difference that was also statistically significant.

PIC Camborough maternal barrows outperform competitors in growth rate and feed efficiency, providing a notable economic advantage. These results highlight the superior profitability and reliability of Camborough genetics for producers. 

For more information about the trial, reach out to your PIC team representative or email PIC.  

[1] PIC ES196